BioRestorative Therapies granted Type B meeting on BRTX-100 BLA pathway

BioRestorative Therapies (BRTX) has been granted a Type B meeting with the U.S. Food and Drug Administration to discuss a potential accelerated Biologics License Application approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of chronic lumbar disc disease. The Type B meeting is scheduled for mid-December.